ID   M14K
AC   CVCL_8102
AS   CVCL_M199
SY   M-14-K; M14
DR   BTO; BTO:0003999
DR   Cosmic; 733822
DR   IARC_TP53; 23629
DR   Wikidata; Q54903474
RX   CelloPub=CLPUB00243;
RX   PubMed=1568228;
RX   PubMed=2323006;
RX   PubMed=9533946;
RX   PubMed=11251971;
RX   PubMed=11283936;
RX   PubMed=23840376;
RX   PubMed=33567673;
CC   Doubling time: 55 hours (PubMed=23840376).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228).
CC   Transformant: ChEBI; CHEBI:46661; Asbestos.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Lung, pleura; UBERON=UBERON_0000977.
DI   NCIt; C45662; Pleural epithelioid mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_U345 ! M14P
OI   CVCL_8103 ! M20 [Human mesothelioma]
SX   Male
AG   43-61Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 17
//
RX   CelloPub=CLPUB00243;
RA   Kahlos K.;
RT   "The expression and possible role of manganese superoxide dismutase in
RT   malignant pleural mesothelioma.";
RL   Thesis PhD (1999), University of Oulu, Finland.
//
RX   PubMed=1568228;
RA   Metcalf R.A., Welsh J.A., Bennett W.P., Seddon M.B., Lehman T.A.,
RA   Pelin-Enlund K., Linnainmaa K., Tammilehto L., Mattson K., Gerwin B.I.,
RA   Harris C.C.;
RT   "p53 and Kirsten-ras mutations in human mesothelioma cell lines.";
RL   Cancer Res. 52:2610-2615(1992).
//
RX   PubMed=2323006; DOI=10.1093/carcin/11.4.673;
RA   Pelin-Enlund K., Husgafvel-Pursiainen K., Tammilehto L., Klockars M.,
RA   Jantunen K., Gerwin B.I., Harris C.C., Tuomi T., Vanhala E.,
RA   Mattson K., Linnainmaa K.;
RT   "Asbestos-related malignant mesothelioma: growth, cytology,
RT   tumorigenicity and consistent chromosome findings in cell lines from
RT   five patients.";
RL   Carcinogenesis 11:673-681(1990).
//
RX   PubMed=9533946; DOI=10.1165/ajrcmb.18.4.2943;
RA   Kahlos K., Anttila S., Asikainen T.M., Kinnula K., Raivio K.O.,
RA   Mattson K., Linnainmaa K., Kinnula V.L.;
RT   "Manganese superoxide dismutase in healthy human pleural mesothelium
RT   and in malignant pleural mesothelioma.";
RL   Am. J. Respir. Cell Mol. Biol. 18:570-580(1998).
//
RX   PubMed=11251971; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1094>3.0.CO;2-M;
RA   Kettunen E., Nissen A.-M., Ollikainen T., Taavitsainen M., Tapper J.,
RA   Mattson K., Linnainmaa K., Knuutila S., El-Rifai W.;
RT   "Gene expression profiling of malignant mesothelioma cell lines: cDNA
RT   array study.";
RL   Int. J. Cancer 91:492-496(2001).
//
RX   PubMed=11283936; DOI=10.1002/1097-0142(20010401)91:7<1349::AID-CNCR1138>3.0.CO;2-D;
RA   Kahlos K., Soini Y., Sormunen R., Kaarteenaho-Wiik R., Paakko P.,
RA   Linnainmaa K., Kinnula V.L.;
RT   "Expression and prognostic significance of catalase in malignant
RT   mesothelioma.";
RL   Cancer 91:1349-1357(2001).
//
RX   PubMed=23840376; DOI=10.1371/journal.pone.0065903;
RA   Szulkin A., Nilsonne G., Mundt F., Wasik A.M., Souri P., Hjerpe A.,
RA   Dobra K.;
RT   "Variation in drug sensitivity of malignant mesothelioma cell lines
RT   with substantial effects of selenite and bortezomib, highlights need
RT   for individualized therapy.";
RL   PLoS ONE 8:E65903-E65903(2013).
//
RX   PubMed=33567673; DOI=10.3390/cancers13040685;
RA   Keller M., Reis K., Hjerpe A., Dobra K., Aspenstrom P.;
RT   "Cytoskeletal organization correlates to motility and invasiveness of
RT   malignant mesothelioma cells.";
RL   Cancers (Basel) 13:685.1-685.20(2021).
//